New England Journal of Medicine Archives

The power of three: triplet drug combination slows disease progression in patients with advanced kidney cancer

Published in The New England Journal of Medicine (1) results of the phase 3 COSMIC-313 trial show that the addition…

POSITIVE results show that temporarily discontinuing endocrine therapy to attempt pregnancy after breast cancer does not increase the short-term risk of disease relapse

Published in The New England Journal of Medicine (1), first results of the international POSITIVE study co-authored by VHIO’s Cristina…

Efficacy of the FGFR inhibitor futibatinib in metastatic cholangiocarcinoma

Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…